Lee's Pharmaceutical Holdings (STU:L1PA) EPS (Basic): €0.02 (TTM As of Dec. 2025)


STU:L1PA Lee's Pharmaceutical Holdings Ltd STU:L1PA
74 GF Score
Price €0.11
GF Value €0.18
! 5 Warning Signs
View Full Analysis

What is Lee's Pharmaceutical Holdings EPS (Basic)?

Lee's Pharmaceutical Holdings STU:L1PA -3.51% 74 EPS (Basic) is €0.02 as of Dec. 2025. GuruFocus rates STU:L1PA with a GF Score™ of 74/100 and a GF Value™ of €0.18. The stock has 5 warning signs investors should review.

Lee's Pharmaceutical Holdings's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.02.

Lee's Pharmaceutical Holdings's EPS (Diluted) for the six months ended in Dec. 2025 was €0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.02.

Lee's Pharmaceutical Holdings's EPS without NRI for the six months ended in Dec. 2025 was €0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.02.

During the past 12 months, Lee's Pharmaceutical Holdings's average EPS without NRIGrowth Rate was -7.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Lee's Pharmaceutical Holdings's highest 3-Year average EPS without NRI Growth Rate was 58.70% per year. The lowest was -55.40% per year. And the median was 11.20% per year.

Lee's Pharmaceutical Holdings  (STU:L1PA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lee's Pharmaceutical Holdings EPS (Basic) Related Terms

Lee's Pharmaceutical Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Lee's Pharmaceutical Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lee's Pharmaceutical Holdings EPS (Basic) Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.01 0.00 0.02 0.02

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 0.01 0.01
STU:L1PA
74GF Score
Lee's Pharmaceutical Holdings Ltd STU:L1PA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lee's Pharmaceutical Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lee's Pharmaceutical Holdings's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(10.091-0)/588.835
=0.02

Lee's Pharmaceutical Holdings's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(2.717-0)/588.835
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €0.02 mean?
Lee's Pharmaceutical Holdings (STU:L1PA) has a EPS (Basic) of €0.02 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lee's Pharmaceutical Holdings and its competitors.
Is Lee's Pharmaceutical Holdings' EPS (Basic) too high?
Lee's Pharmaceutical Holdings' current EPS (Basic) is €0.02. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' EPS (Basic) compare to ZTS?
Lee's Pharmaceutical Holdings' EPS (Basic) of €0.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lee's Pharmaceutical Holdings and its competitors. Lee's Pharmaceutical Holdings's current EPS (Basic) is €0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (STU:L1PA) has a current EPS (Basic) of €0.02. The stock's GF Value™ is €0.18, compared to a current price of €0.11 — trading 40% below its estimated fair value. The current EPS (Basic) is €0.02. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (STU:L1PA), the current EPS (Basic) is €0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lee's Pharmaceutical Holdings (STU:L1PA) Overvalued in 2026?

Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued. The current stock price of €0.11 is trading 40% below its estimated GF Value™ of €0.18.

Key valuation signals for STU:L1PA:

  • EPS (Basic): €0.02
  • GF Value™: €0.18 vs. price of €0.11 (40% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the STU:L1PA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lee's Pharmaceutical Holdings Business Description

Other Exchanges 00950:Hong Kong
Address Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score

Get the complete analysis for STU:L1PA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.18
GF Value